Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD19 CAR-T Cells in R/R B-ALL
NCT03671460Phase 1Unknown
- Sponsor
- Tianjin Mycure Medical Technology Co., Ltd.
- Start
- Sep 2018
- Primary completion
- Jan 2020
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CD19 CAR-T cells in B cell acute lymphoblastic leukemia (B-ALL), sponsored by Tianjin Mycure Medical Technology Co., Ltd. Primary endpoint: Percentage of adverse events at 6 months. Status: unknown.
02
Drugs
CD19 CAR-T cells
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on NCT03671460.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03671460.